Association between COVID-19 vaccination and atrial arrhythmias in individuals with cardiac implantable electronic devices.
COVID‐19
atrial arrhythmia
atrial fibrillation
implantable cardioverter defibrillator
mRNA
pacemaker
vaccine
ventricular tachycardia
Journal
Journal of cardiovascular electrophysiology
ISSN: 1540-8167
Titre abrégé: J Cardiovasc Electrophysiol
Pays: United States
ID NLM: 9010756
Informations de publication
Date de publication:
22 Jul 2024
22 Jul 2024
Historique:
revised:
16
06
2024
received:
22
03
2024
accepted:
07
07
2024
medline:
23
7
2024
pubmed:
23
7
2024
entrez:
23
7
2024
Statut:
aheadofprint
Résumé
The impact of mRNA-based coronavirus disease-2019 (COVID-19) vaccines on atrial arrhythmias (AA) and ventricular arrhythmias incidence is unknown. BIOTRONIK Home Monitoring data and Medicare Claims data were utilized to identify individuals implanted with a cardiac implantable electronic device (CIED) between 2010 and 2020 who received one or more doses of COVID-19 vaccine in 2021. The burden of AA (%) in the 3 months postvaccination was compared to those noted in the preceding 3 months using the Wilcoxon signed rank test. Sub-analyses comparing the effects of the influenza vaccine against the COVID-19 vaccine were also evaluated for individuals who received the influenza vaccine in 2020. A 1:1 propensity score match comparison between COVID-19 vaccine and non-vaccinated patients was also performed. First and second doses of the COVID-19 vaccine were administered to 7757 and 6579 individuals with a CIED (age 76.2 ± 9.0 years, 49% males), respectively. While a small but statistically significant increase in the burden of AA was noted in the 3 months postvaccination compared to the preceding 3 months after the first dose of the COVID-19 vaccine (0.43 ± 9.04%, p = .028) a similar rise in AA was found following the influenza vaccine and for matched patients who did not receive the COVID-19 vaccine. No significant difference in device therapies was seen pre- and postvaccination. Though we report a small but significant increase in the number of CIED-detected AAs following vaccination for COVID-19 over a 3-month window, we believe these results correlate more with time and the progressive nature of AF rather than the vaccine itself. While these data should not dissuade from the use of these vaccines, increased vigilance and prompt treatment of AF is required for high-risk groups, specifically males over 70 years of age, following vaccination.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 Wiley Periodicals LLC.
Références
Organization WH. Background Paper on COVID‐19 Disease and Vaccines: Prepared by the Strategic Advisory Group of Experts (SAGE) on Immunization Working Group on COVID‐19 Vaccines. World Health Organization; 22 December 2020.
SteelFisher GK, Blendon RJ, Caporello H. An uncertain public‐encouraging acceptance of Covid‐19 vaccines. N Engl J Med. 2021;384:1483‐1487.
Heidecker B, Dagan N, Balicer R, et al. Myocarditis following COVID‐19 vaccine: incidence, presentation, diagnosis, pathophysiology, therapy, and outcomes put into perspective. A clinical consensus document supported by the Heart Failure Association of the European Society of Cardiology (ESC) and the ESC Working Group on myocardial and pericardial diseases. Eur J Heart Fail. 2022;24:2000‐2018.
Kumar A, Shariff M, Bhat V, DeSimone C, Deshmukh A. Atrial fibrillation after vaccination for COVID‐19: analysis of the vaccine adverse event reporting system. J Interv Card Electrophysiol. 2022;65:1‐2.
Patone M, Mei XW, Handunnetthi L, et al. Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID‐19 vaccination or SARS‐CoV‐2 infection. Nature Med. 2022;28:410‐422.
Deshmukh AJ, Harrell C, Hicks J, et al. Physical activity in cardiac implantable electronic device recipients during the COVID‐19 pandemic. Mayo Clin Proc. 2022;97:1493‐1500.
Mullane S, Harrell C, Tsitiridis N, Upadhyay G, Cheung JW, Hayes D. Medicare claims‐based evaluation of atrial fibrillation within implantable cardiac monitor patients with cryptogenic stroke. J Interv Card Electrophysiol. 2023;66:1795‐1797.
Find your COVID‐19 vaccine CPT® Codes. American Medical Association. https://www.ama-assn.org/find-COVID-19-vaccine-codes
Flu Shot. CMS.gov. https://www.cms.gov/flu-provider
Chronic Conditions Data Warehouse (2017) 27 CCW Chronic Conditions (1999–2021). CMS Medicare and Medicaid research data. Accessed 5 May 2023. https://www2.ccwdata.org/web/guest/condition-categories-chronic
Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid‐19 vaccine. N Engl J Med. 2020;383:2603‐2615.
Kerr S, Joy M, Torabi F, et al. First dose ChAdOx1 and BNT162b2 COVID‐19 vaccinations and cerebral venous sinus thrombosis: a pooled self‐controlled case series study of 11.6 million individuals in England, Scotland, and Wales. PLoS Med. 2022;19:e1003927.
Barda N, Dagan N, Ben‐Shlomo Y, et al. Safety of the BNT162b2 mRNA Covid‐19 vaccine in a nationwide setting. N Engl J Med. 2021;385:1078‐1090.
Kadali RAK, Janagama R, Peruru S, Malayala SV. Side effects of BNT162b2 mRNA COVID‐19 vaccine: a randomized, cross‐sectional study with detailed self‐reported symptoms from healthcare workers. Int J Infect Dis. 2021;106:376‐381.
Musikantow DR, Turagam MK, Sartori S, et al. Atrial fibrillation in patients hospitalized with COVID‐19. JACC Clin Electrophysiol. 2021;7:1120‐1130.
Agarwal S, Munir MB, Stavrakis S, Piccini JP, Asad ZUA. The impact of atrial fibrillation on outcomes in patients hospitalized with COVID‐19. Eur J Intern Med. 2023;111:127‐129.
Bernstein HM, Paciotti B, Srivatsa UN. Incidence and implications of atrial fibrillation in patients hospitalized for COVID compared to non‐COVID pneumonia: a multicenter cohort study. Heart Rhythm O2. 2023;4:3‐8.
Donniacuo M, De Angelis A, Rafaniello C, et al. COVID‐19 and atrial fibrillation: intercepting lines. Front Cardiovasc Med. 2023;10:1093053.
Kensara R, Aljuhani O, Korayem GB, et al. Incidence and clinical outcomes of new‐onset atrial fibrillation in critically ill patients with COVID‐19: a multicenter cohort study. Clin Appl Thromb Hemost. 2023;29:107602962311561.
Vasbinder A, Meloche C, Azam TU, et al. Relationship between preexisting cardiovascular disease and death and cardiovascular outcomes in critically ill patients with COVID‐19. Circ Cardiovasc Qual Outcomes. 2022;15:e008942.
Zuin M, Bilato C. Increase in atrial fibrillation‐related mortality in the United States during the COVID‐19 pandemic. Heart Rhythm. 2023;20:163‐164.
Thakkar S, Arora S, Kumar A, et al. A systematic review of the cardiovascular manifestations and outcomes in the setting of coronavirus‐19 disease. Clin Med Insight Cardiol. 2020;14:117954682097719.
Machado BAS, Hodel KVS, Fonseca L, et al. The importance of vaccination in the context of the COVID‐19 pandemic: a brief update regarding the use of vaccines. Vaccines. 2022;10:591.
Galand V, Hwang E, Gandjbakhch E, et al. Impact of COVID‐19 on the incidence of cardiac arrhythmias in implantable cardioverter defibrillator recipients followed by remote monitoring. Arch Cardiovasc Dis. 2021;114:407‐414.
Sangpornsuk N, Rungpradubvong V, Tokavanich N, et al. Arrhythmias after SARS‐CoV‐2 vaccination in patients with a cardiac implantable electronic device: a multicenter study. Biomedicines. 2022;10:2838.
Chang TY, Chao TF, Liu CJ, et al. The association between influenza infection, vaccination, and atrial fibrillation: a nationwide case‐control study. Heart Rhythm. 2016;13:1189‐1194.